AT1 chart, page-364

As I stated many times before the key problem with this company is volume.
It states it is building its US exposure with a BDM but it useless having that resource when you can produce volume for such a market.
This is why Bondi Partners cannot get a deal.
Elume are producing 30m/month and rising.
HIV test yes have huge potential in 3rd World counties but they want only a cheap product.
Atomo cannot make volume hence they get bits and pieces small orders that dont add up to much.
John talks a big book but cannot deliver.
The partners so far have been crap.
Very disappointing management